Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Capital Leases (2023 - 2025)

bioAffinity Technologies (BIAF) has disclosed Capital Leases for 3 consecutive years, with $532759.0 as the latest value for Q4 2025.

  • Quarterly Capital Leases rose 19.87% to $532759.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $532759.0 through Dec 2025, up 19.87% year-over-year, with the annual reading at $532759.0 for FY2025, 19.87% up from the prior year.
  • Capital Leases for Q4 2025 was $532759.0 at bioAffinity Technologies, up from $1998.0 in the prior quarter.
  • The five-year high for Capital Leases was $929570.0 in Q3 2023, with the low at $1998.0 in Q3 2025.
  • Average Capital Leases over 3 years is $500813.4, with a median of $537883.0 recorded in 2024.
  • Peak annual rise in Capital Leases hit 19.87% in 2025, while the deepest fall reached 99.63% in 2025.
  • Over 3 years, Capital Leases stood at $835467.0 in 2023, then tumbled by 46.8% to $444448.0 in 2024, then rose by 19.87% to $532759.0 in 2025.
  • According to Business Quant data, Capital Leases over the past three periods came in at $532759.0, $1998.0, and $3942.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.